Business Context and Reporting Period
This Form 8-K Current Report was filed by X4 Pharmaceuticals, Inc. on July 25, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol XFOR. The report addresses a specific corporate governance event rather than periodic financial performance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer departures and does not contain financial statements or operational metrics.
Material Changes
The material change disclosed is the resignation of Derek Meisner from his positions as Chief Legal Officer and Corporate Secretary. His resignation is effective August 22, 2022. The company stated that Mr. Meisner is resigning to pursue another opportunity and that the departure is not the result of any disagreement with the Company or its Board of Directors regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies were disclosed in this report other than the standard disclosure of the officer's departure.
Key Facts for Investor Verification
- Derek Meisner is resigning as Chief Legal Officer and Corporate Secretary effective August 22, 2022.
- The resignation is voluntary and unrelated to any disagreement with the company.
- Adam Mostafa, Chief Financial Officer, signed the report on behalf of the company on July 29, 2022.
- No financial data or operational updates are included in this specific filing.